Behcet disease drug Market Is Likely to Experience a Tremendous Growth by 2029
Behcet disease drug Market is anticipated to grow at a considerable CAGR during the forecast period. The use of biosimilars has increased in recent times. It will also rise in the future as biosimilars serve as a low-cost, easy option. Biosimilars are medicines that are close to biological drugs. They have the same characteristics, structure, and composition as biological drugs. Biologic drugs are those drugs that are made from several pieces of protein. Any brand drug has a parallel biosimilar to it. These biosimilars are safe and secure to consume when their efficacy is concerned. A drug that is of a particular brand also has its generic version. Generic drugs are clinically tested the same way as a biological drugs. It is expected that with time, biosimilar drugs would reduce the price of biological drugs. It all depends on how many biosimilar drugs are approved, tested, and become available for use in clinical purposes.
Biosimilars are used for treatment in Behcet or other
inflammatory disease. For instance, in Oct 2021, FDA gives approval to
Boehringer Ingelheim’s Cyltezo. This drug can be used as a substitute for
Humira drugs. Humira drug is prescribed in various inflammatory conditions.
Multiple biosimilars for Humira have been launched to date but no drug could
make up to the market. Biosimilar drugs in the US have prices 15 to 35 percent
lower than their reference products. There are 5 other biosimilars for Humira
which will be launched at the end of 2023.
To Request a Sample of our Report on Behcet disease drug
Market: https://www.omrglobal.com/request-sample/behcet-disease-drug-market
Market Coverage
·
The market number available for – 2022-2030
·
Base year- 2022
·
Forecast period- 2023-2030
Segment Covered-
·
By Drug
·
By route of administration
Regions Covered-
·
North America
·
Europe
·
Asia-Pacific
·
Rest of the World
Competitive Landscape-
Abbvie Inc., Celgene Corp., Cell Medica Ltd., Cohersu biosciences Inc., Genor
biopharma Corp.Ltd. and others
Behcet disease drug Market Report by
Segment
By Drug
·
Corticosteroid
·
Adalimumab Biosimilar
·
Infliximab Biosimilar
·
Apremilast
·
Canakinumab
By route of administration
·
Oral
·
Intravenous
·
Intramuscular
·
Topical
A
full Report of Behcet disease drug Market is Available @ https://www.omrglobal.com/industry-reports/behcet-disease-drug-market
Behcet disease drug Market Report by Region
North America
·
United States
·
Canada
Europe
·
UK
·
Germany
·
Spain
·
France
·
Italy
·
Rest of Europe
Asia-Pacific
·
India
·
China
·
Japan
·
South Korea
·
Rest of APAC
Rest of the World
·
Latin America
·
Middle East & Africa
Company Profiles
·
Abbott Laboratories
·
Biocon Ltd.
·
F. Hoffmann-La Roche Ltd.
·
Hospira Inc.
·
Intas Pharmaceutical
·
Novartis AG
·
Panacea Biotec Ltd.
·
R Pharm
Reasons to buy from us –
1. We cover more than
15 major industries, further segmented into more than 90 sectors.
2. More than 120
countries are for analysis.
3. Over 100+ paid
data sources mined for investigation.
4. Our expert
research analysts answer all your questions before and after purchasing your
report.
About Orion Market Research
Orion Market
Research (OMR) is a market research and consulting company known for its crisp
and concise reports. The company is equipped with an experienced team of
analysts and consultants. OMR offers quality syndicated research reports,
customized research reports, consulting and other research-based services. The
company also offer Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services
through another subsidiary Encanto Technologies.
Media
Contact:
Company
Name: Orion Market Research
Contact
Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact
no: +91 7803040404
Comments
Post a Comment